Phase III trial of DaxibotulinumtoxinA in patients with cervical dystonia

Trial Profile

Phase III trial of DaxibotulinumtoxinA in patients with cervical dystonia

Planning
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2017

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Torticollis
  • Focus Registrational; Therapeutic Use
  • Sponsors Revance Therapeutics
  • Most Recent Events

    • 29 Dec 2017 According to a Revance Therapeutics media release, the company plans to proceed to phase III program in cervical dystonia based on results from phase II trial and guidance from the FDA and EMA. The phase III program is planned to commence in the second quarter of 2018.
    • 01 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top